Szajnman S H, Yan W, Bailey B N, Docampo R, Elhalem E, Rodriguez J B
Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, RA-1428 Buenos Aires, Argentina.
J Med Chem. 2000 May 4;43(9):1826-40. doi: 10.1021/jm9905007.
As a part of our project directed at the search of new chemotherapeutic agents against American trypanosomiasis (Chagas' disease), several drugs possessing the 4-phenoxyphenoxy skeleton and other closely related structures employing the thiocyanate moiety as polar end group were designed, synthesized, and evaluated as antiproliferative agents against Trypanosoma cruzi, the parasite responsible for this disease. These thiocyanate analogues were envisioned bearing in mind the potent activity shown by 4-phenoxyphenoxyethyl thiocyanate (compound 8) taken as lead drug. This compound had previously proved to be an extremely active growth inhibitor against T. cruzi with IC(50) values ranging from the very low micromolar level in epimastigotes to the low nanomolar level in the intracellular form of the parasite. Of the designed compounds, the ethyl thiocyanate drugs connected to nonpolar skeletons, namely, arylthio, 2,4-dichlorophenoxy, ortho-substituted aryloxy, and 2-methyl-4-phenoxyphenoxy (compounds 15, 34, 47, 52, 72, respectively), were shown to be very potent antireplicative agents against T. cruzi. On the other hand, conformationally restricted analogues as well as branched derivatives at the aliphatic side chain were shown to be moderately active against T. cruzi growth. The biological activity of drugs bearing the thiocyanate group correlated quite well with the activity exhibited by their normal precursors, the tetrahydropyranyl ether derivatives, when bonded to the same nonpolar skeleton. Compounds having the tetrahydropyranyl moeity as polar end were proportionally much less active than sulfur-containing derivatives in all cases. Drugs 47 and 72 also resulted to be very active against the amastigote form of the parasite growing in myoblasts; however, they were slightly less active than the lead drug 8. On the other hand, compounds 34 and 52 were almost devoid of activity against myoblasts. Surprisingly, the dithio derivative 15 was toxic for myoblasts.
作为我们旨在寻找抗美洲锥虫病(恰加斯病)新化疗药物项目的一部分,设计、合成并评估了几种具有4 - 苯氧基苯氧基骨架以及其他以硫氰酸酯部分作为极性端基的紧密相关结构的药物,作为针对导致该病的寄生虫克氏锥虫的抗增殖剂。设计这些硫氰酸酯类似物时,考虑到以硫氰酸4 - 苯氧基苯氧基乙酯(化合物8)作为先导药物所显示出的强效活性。该化合物先前已被证明是一种对克氏锥虫极具活性的生长抑制剂,其IC(50)值范围从在无鞭毛体中极低的微摩尔水平到在寄生虫细胞内形式中低纳摩尔水平。在所设计的化合物中,连接到非极性骨架上的硫氰酸乙酯药物,即芳硫基、2,4 - 二氯苯氧基、邻位取代的芳氧基和2 - 甲基 - 4 - 苯氧基苯氧基(分别为化合物15、34、47、52、72),显示出是针对克氏锥虫的非常有效的抗复制剂。另一方面,构象受限类似物以及脂肪族侧链上的支链衍生物显示出对克氏锥虫生长具有中等活性。带有硫氰酸酯基团的药物的生物活性与其正常前体(四氢吡喃基醚衍生物)连接到相同非极性骨架时所表现出的活性相当好地相关。在所有情况下,以四氢吡喃基作为极性端基的化合物的活性比含硫衍生物成比例地低得多。药物47和72对在成肌细胞中生长的寄生虫的无鞭毛体形式也非常有活性;然而,它们的活性略低于先导药物8。另一方面,化合物34和52对成肌细胞几乎没有活性。令人惊讶的是,二硫衍生物15对成肌细胞有毒性。